biostudies-literatureUnknown13Kong F<h4>Background</h4>Prophylactic medication in clinical detoxification programs for the treatment of medication overuse headache is still debated. Gastrodin, a main bioactive constituent of <i>Rhizoma Gastrodiae</i>, has been applied clinically to treat primary headache for more than 30 years in China due to its potential analgesic and anti-migraine mechanisms. However, clinical evidence supporting its routing use in MOH is insufficient. The present study aims to investigate the efficacy and tolerability of oral gastrodin in medication overuse headache.<h4>Methods</h4>A multicenter, randomized, double-blind, parallel, placebo-controlled trial will be performed. A target sample size of 186 patients who fulfill the International Classification of Headache Disorders 3rd version (ICHD-3) criterFrontiers in neurology1095298https://www.ebi.ac.uk/biostudies/studies/S-EPMC9993247biostudies-literatureEfficacy and tolerability of oral gastrodin for medication overuse headache (EASTERN): Study protocol for a multicenter randomized double-blind placebo-controlled trial.PMC9993247Liu HMa SKong FGeng JXu JBuse DCfalseEfficacy and tolerability of oral gastrodin for medication overuse headache (EASTERN): Study protocol for a multicenter randomized double-blind placebo-controlled trial.<h4>Background</h4>Prophylactic medication in clinical detoxification programs for the treatment of medication overuse headache is still debated. Gastrodin, a main bioactive constituent of <i>Rhizoma Gastrodiae</i>, has been applied clinically to treat primary headache for more than 30 years in China due to its potential analgesic and anti-migraine mechanisms. However, clinical evidence supporting its routing use in MOH is insufficient. The present study aims to investigate the efficacy and tolerability of oral gastrodin in medication overuse headache.<h4>Methods</h4>A multicenter, randomized, double-blind, parallel, placebo-controlled trial will be performed. A target sample size of 186 patients who fulfill the International Classification of Headache Disorders 3rd version (ICHD-3) criter2022-01-01T00:00:00Z20222025-04-04T11:27:09.824Z2025-04-04T11:27:09.824ZS-EPMC99932473691086310.3389/fneur.2022.1095298